Eltrombopag is a prescription medication used for the treatment of certain conditions underlying thrombocytopenia, defining an abnormally low platelet count. Due to the specificness of the aliment it was designed to treat, it was designated an orphan drug in the United States and European Union. Resulting in research into this product to be declared a matter of public policy facilitating the allotment of government funds to augment the development process, which would not have been otherwise cost-effective for manufacturers. Initially developed in cooperation between the two pharmaceutical products companies GlaxoSmithKline and Ligand Pharmaceuticals, the patent was approved in 2008 by the FDA in the United States and it can be found globally from distributors at varying price points under brand names including Promacta, Revolade, Elbonix, Idiopag, and Treptora. Under which both these pharmaceutical manufacturers and suppliers often list it as for sale or wholesale. Eltrombopag belongs to a family of drugs called thrombopoietin (TPO) receptor agonists, specifically, it is a small molecule capable of binding to the c-mpl (TpoR) receptor whose normal physiological target is that of the thrombopoietin hormone. As the glycoprotein thrombopoietin, also known as megakaryocyte growth and development factor (MGDF), is responsible for the stimulation of megakaryocyte proliferation and differentiation, and megakaryocyte are bone marrow cells that bud off into large numbers of platelets. Antagonistic binding of this medicine to the TpoR thus upregulates thrombopoietin’s downstream functions culminating in an increase of platelet production and subsequent diminution in disease symptom and effects.

Eltrombopag manufacturers and suppliers typically list it for sale in tablet, film-coated tablet, and oral suspension form, with individual packaging depending on specific manufacturer company or distributor arrangements. Due to the prescribed nature, it can only be administered under the digression of a specialist medical professional and is taken orally, with dosage tailored to the individual, starting low and subsequently adjusted upon response. Typically it is taken once a day on an empty stomach at least 1 hour before or 2 hours post eating, with exclusion times being extended upon consumption of calcium-rich food as this can influence adverse effects. Oral suspensions are similar, with it being recommended to mix with cool or cold water and to dispose of any remaining liquid after 30 minutes using an appropriate disposal method. Eltrombopag is available to order on our global online Pipelinepharma marketplace. Facilitating rapid sourcing and discovery of a large array of listings from an assortment of verified B2B manufacturers and distributors offering wholesale for purchase. A current search at the time of writing reveals 6 Pipelinepharma trusted sellers located in countries including the European Union, Argentina, Turkey, and Bangladesh. As with all products listed online on the Pipelinepharma marketplace, the specific cost and details of the listing remain negotiable online between both B2B parties. However, upon the manufacturers, disturber, or supplier’s discretion they can choose to include the desired price and specific details within their list to expedite transactions. If so, this will be indicated and an orange ‘Accept’ button will be displayed alongside a ‘Negotiate’ button. If no requested price is supplied a ‘Get offer’ button will be displayed instead.

Depends entirely on the pharmacy you visit, Eltrombopag oral powder for reconstitution 12.5 mg costs roughly $5,898 for a package of 30 powder for reconstitution. Prices are only acceptable for cash paying consumers and do not apply to insurance programmes. Some deals can be printed directly from the site, while others need registration.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Empagliflozin offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for these substance manufacturers and Eltrombopag suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Empagliflozin. Also, each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where Empagliflozin is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and ordering process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers or Eltrombopag suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are onboarded on the platform. This allows us to screen Empagliflozin manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.